Orthofix Medical Inc. (NASDAQ:OFIX) Given Average Recommendation of “Hold” by Analysts

Shares of Orthofix Medical Inc. (NASDAQ:OFIX) have received an average recommendation of “Hold” from the five ratings firms that are currently covering the company, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average 12 month price target among brokers that have covered the stock in the last year is $18.00.

OFIX has been the topic of a number of recent analyst reports. Roth Capital raised shares of Orthofix Medical from a “neutral” rating to a “buy” rating in a research note on Wednesday, May 8th. Roth Mkm raised shares of Orthofix Medical from a “neutral” rating to a “buy” rating and increased their price target for the stock from $15.00 to $20.00 in a research note on Wednesday, May 8th. StockNews.com upgraded shares of Orthofix Medical from a “sell” rating to a “hold” rating in a report on Wednesday, May 8th. Finally, JMP Securities restated a “market perform” rating on shares of Orthofix Medical in a report on Monday, April 22nd.

Institutional Investors Weigh In On Orthofix Medical

Several hedge funds and other institutional investors have recently added to or reduced their stakes in OFIX. Gladius Capital Management LP increased its stake in Orthofix Medical by 55.2% during the 4th quarter. Gladius Capital Management LP now owns 2,841 shares of the medical device company’s stock worth $38,000 after buying an additional 1,010 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Orthofix Medical by 30.4% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,516 shares of the medical device company’s stock worth $101,000 after buying an additional 1,752 shares during the period. Teza Capital Management LLC purchased a new stake in Orthofix Medical during the 3rd quarter worth $133,000. Arizona State Retirement System purchased a new stake in Orthofix Medical during the 4th quarter worth $138,000. Finally, State Board of Administration of Florida Retirement System increased its stake in Orthofix Medical by 34.7% during the 1st quarter. State Board of Administration of Florida Retirement System now owns 13,562 shares of the medical device company’s stock worth $197,000 after buying an additional 3,490 shares during the period. Hedge funds and other institutional investors own 89.76% of the company’s stock.

Orthofix Medical Stock Performance

Shares of OFIX opened at $13.48 on Friday. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.19 and a current ratio of 2.65. The company has a market capitalization of $505.89 million, a price-to-earnings ratio of -3.99 and a beta of 1.07. The company’s 50 day simple moving average is $13.72 and its 200 day simple moving average is $13.71. Orthofix Medical has a 1 year low of $9.57 and a 1 year high of $21.60.

Orthofix Medical (NASDAQ:OFIX) last posted its quarterly earnings results on Tuesday, May 7th. The medical device company reported ($0.95) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.41). The company had revenue of $188.61 million for the quarter, compared to analysts’ expectations of $183.40 million. Orthofix Medical had a negative return on equity of 14.24% and a negative net margin of 16.64%. On average, sell-side analysts predict that Orthofix Medical will post -1.88 EPS for the current year.

About Orthofix Medical

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.